Published in Lab Law Weekly, June 10th, 2005
Ciphergen's total revenue was $6.6 million in the first quarter of 2005 as compared to $13.3 million in the first quarter of 2004. Ciphergen's net loss was $9.3 million in the first quarter of 2005 as compared to $7.5 million in the first quarter of 2004.
At March 31, 2005, the company's cash and investments were $32.2 million. Total long-term debt totaled $28.4 million, of which $28.2 million was convertible debt.
"We have made solid progress in 2005 in our diagnostics division, in particular in optimizing ovarian cancer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.